The merger of Indegene Healthcare Germany GmbH (transferor company) with Trilogy Writing & Consulting GmbH (transferee company) was registered with the Commercial Register of the Local Court (Amtsgericht) of Frankfurt am Main on September 9, 2026. Consequently, the merger became effective on the same date.
Following the merger, Indegene Healthcare Germany GmbH ceased to exist as a separate legal entity. The name of the surviving entity, Trilogy Writing & Consulting GmbH, was changed to Indegene Healthcare Germany GmbH on September 9, 2026, and it will operate under this new name.
Rationale and Impact
- The merger is described as an internal reorganization and part of an internal restructuring.
- The company explicitly states the merger does not have any material impact on the business operations, shareholding pattern, or financial position of Indegene Limited.
Financial and Operational Details
- Projected Revenue: The surviving entity (Indegene Healthcare Germany GmbH) has a projected revenue of Euro 20,100,000 for FY 2026-27.
- Areas of Business:
- Indegene Healthcare Germany GmbH operated in healthcare and life sciences services.
- Trilogy Writing & Consulting GmbH operated in medical writing, regulatory, clinical, and consulting services for the life sciences industry.
- Consideration: The merger did not involve any cash consideration or share exchange.
- Shareholding: There is no change in the shareholding pattern of the listed entity (Indegene Limited) as a result of this merger.
- Related Party Transaction: The disclosure states the question of whether the transaction falls within related party transactions is "Not Applicable."